联系方式办公电话：
电子邮箱：wangxd@mail.sysu.edu.cn
办公地址：广州市大学城外环东路132号 中山大学药学院
?简单介绍王雪丁，中山大学药学院教授，博士生导师， 美国Tufts大学作博士后。中国药理学会-SERVIER青年药理学工作者奖获得者。 中国药理学会药物基因组学专业委员会委员，中国药理学会表观遗传药理学专业委员会委员。中国临床药理学杂志编委。研究方向为临床药理学与药物基因组学。在靶向抗肿瘤药物、抗癫痫药物及IBD治疗药物的个体化研究中获得具有重要临床指导意义的成果。 主持国家自然科学基金4项，作为课题骨干参与多项国家重点研发项目、“重大新药创制”科技重大专项及国家自然基金重点项目。发表论文70余篇（高水平期刊收录50余篇）。申请专利多项。
?研究方向药物代谢、药物基因组学及临床合理用药。
?
教育经历2003/09 – 2006/06，中山医科大学，药学院，博士
1997/09 – 2000/06，中山医科大学，医学院，硕士
1992/09 –1997/06，大连医科大学，医学院，学士
?
工作经历2000.07 ~ 至今：中山大学药学院药物代谢与药代动力学实验室、中山大学临床药理研究所
2008.9 ~ 2009.10：美国Tufts大学 博士后研究
?
科研项目1.科技部新药研发重大专项，2012.07～2018.06，分题负责。
2.国家自然科学基金面上项目，2020.01～2023.12，负责。
3.国家自然科学基金面上项目，2015.01～2018.12，负责。
4.国家自然科学基金面上项目，2012.01～2015.12，负责。
5.国家自然科学基金面上项目，2009.01～2011.12，负责。
?
近5年发表的主要高水平论文：1.Xin S#, Zhao Y#, Wang C, Huang Y, Zhuang W, Ma Y, Huang M, Xu X, Wang X*, Zhang L*. ?Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients. ?Pharmacogenomics J. 2019 Oct 30. doi: 10.1038/s41397-019-0115-z.
2. Zhu X#, Chao K#, Li M, Xie W, Zheng H, Zhang JX, Hu PJ, Huang M, Gao X*, Wang XD*. ?Nucleoside diphosphate-linked moiety X-type motif 15 R139C genotypes impact 6-thioguanine nucleotide cut-off levels to predict thiopurine-induced leukopenia in Crohn's disease patients. ?World J Gastroenterol. 2019 Oct 14;25(38):5850-5861
3. Guan S, Chen X, Wang F, Xin S, Feng W, Zhu X, Liu S, Zhuang W, Zhou S, Huang M, Wang X*, Zhang L*. ?Development and validation of a sensitive LC-MS/MS method for determination of gefitinib and its major metabolites in human plasma and its application in non-small cell lung cancer patients. ?J Pharm Biomed Anal. 2019 Aug 5;172:364-371.
4. Zhuang W#; Xie JD#; Zhou S, Zhou ZW; Zhou Y; Sun XW; Yuan XH; Huang M; Liu S; Xin S; Su QB; Qiu HB*; Wang XD*. Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? Cancer Med 2018,7 (2): 317-324 ?
5. Wen DS#; Chen ZY#; Yang C; Liu HB; Li HL; Chen J; Dai QL; Zhong GP; Qin JM; Ni GZ; Huang M; Zhou LM*; Wang XD*. A rapid and simple HPLC-MS/MS method for the simultaneous quantification of valproic acid and its five metabolites in human plasma and application to study pharmacokinetic interaction in Chinese epilepsy patients. J Pharm Biomed Anal 2018, 149 : 448-456
6. Chen J#; Su QB#; Qin JM; Zhou Y; Ruan HL; Chen ZY; Chen ZJ; Li HL; Zhou YF; Zhou S; Wang XD*; Zhou LM*; Huang, M. Correlation of MCT1 and ABCC2 gene polymorphisms with valproic acid resistance in patients with epilepsy on valproic acid. DRUG METAB PHARMACOK 2018:S**05675.
7. Chen J#; Su QB#; Tao YQ; Qin JM; Zhou Y; Zhou S; Li HL; Chen ZJ; Zhou YF; Zhou LM*; Wang XD*; Huang M. ABCC2 rs** is associated with valproic acid concentrations in patients with epilepsy on valproic acid monotherapy. PHARMAZIE.2018 May 1;73(5):279-282
8.Chao K#, Wang X#, Cao Q#, Qian J, Wu K, Zhu X, Yang H, Liang J, Lin L, Huang Z, Zhang Y, Huang Y, Sun Y, Xue X, Huang M, Hu P, Lan P, Gao X*. Combined Detection of NUDT15 Variants Could Highly Predict Thiopurine-induced Leukopenia in Chinese Patients with Inflammatory Bowel Disease: A Multicenter Analysis. INFLAMM BOWEL DIS 2017;23(9):1592-1599.
9.Zhuang W#, Qiu HB#, Chen XM, Yuan XH, Yang LF, Sun XW, Zhou XJ, Huang M, Wang XD*, Zhou ZW*. Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor. BIOMED CHROMATOGR 2017;31(12).
10.Qiu HB#, Zhuang W#, Wu T, Xin S, Lin CZ, Ruan HL, Zhu X, Huang M, Li JL, Hou XY, Zhou ZW*, Wang XD*. Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1. PHARMACOGENOMICS J 2017.
11 .Ma Y#, Xin S#, Huang M, Yang Y, Zhu C, Zhao H, Zhang Y, Chen L, Zhao Y, Li J, Zhuang W, Zhu X, Zhang L*, Wang X*. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters. PHARMACOGENOMICS J 2017;17(4):325-330.
12.Shu W#, Guan S#, Yang X, Liang L, Li J, Chen Z, Zhang Y, Chen L, Wang X*, Huang M*. Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus. Br J Clin Pharmacol 2016;81(2):327-340.
13. Zhu X#, Wang XD#，*, Chao K, Zhi M, Zheng H, Ruan HL, Xin S, Ding N, Hu PJ, Huang M, Gao X*. NUDT15 polymorphisms are better than thiopurine S-methyltransferase as predictor of risk for thiopurine-induced leukopenia in Chinese patients with Crohn's disease. Aliment Pharmacol Ther 2016;44(9):967-975.
14. Li H#, Wang X#, Zhou Y, Ni G, Su Q, Chen Z, Chen Z, Li J, Chen X, Hou X, Xie W, Xin S, Zhou L*, Huang M*. Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid. Int J Neuropsychopharmacol 2015;18(7):v21.
15. Zhou Y#, Wang X#, Li H, Zhang J, Chen Z, Xie W, Zhang J, Li J, Zhou L*, Huang M*. Polymorphisms of ABCG2, ABCB1 and HNF4alpha are associated with Lamotrigine trough concentrations in epilepsy patients. Drug Metab Pharmacokinet 2015;30(4):282-287.